In addition to recent Independence Day festivities, the U.S. biotech space has other reasons to celebrate. The asthma drug developer Upstream Bio topped the ranks for the U.S.’ biggest early-stage biotech investment in June 2022, but manufacturing heavyweight National Resilience, Inc. bagged the private funding top spot with a huge Series D round.
In June 2022, the U.S. private biotech investment scene was stormed by a huge $625 million Series D round raised by National Resilience.
The San Diego-based company was founded in 2020 as the U.S. struggled to handle the manufacturing demand for healthcare products resulting from the COVID-19 pandemic. The company is investing big cash in speeding up the production of a range of therapies including cell and gene therapies in addition to cell-free manufacturing for biologics such as antibodies.
“We have an ambitious goal to reinvent biomanufacturing by bringing new processes and technologies to an industry that hasn’t kept pace with the explosive innovation in drug discovery,” said Resilience CEO Rahul Singhvi in a public statement.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.